Is it True? Evaluating Research about a Therapy Allen F. Shaughnessy, PharmD, MmedEd Tufts University School of Medicine Department of Family Medicine.

Slides:



Advertisements
Similar presentations
Department of O UTCOMES R ESEARCH. Daniel I. Sessler, M.D. Professor and Chair Department of O UTCOMES R ESEARCH The Cleveland Clinic Clinical Research.
Advertisements

Experimental Studies. Types of Experimental Studies Multiple experimental groups Blinds single, double, triple.
Use of Placebos in Controlled Trials. Background The traditional ‘double-blind’ RCT uses a placebo to conceal allocation. There are a number of advantages.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Evidence-based Medicine Journal Club Khalid Bin Abdulrahman Director of Medical Education Center King Saud University.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Basics of Study Design Janice Weinberg ScD Professor of Biostatistics Boston University School of Public Health.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006 Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
BC Jung A Brief Introduction to Epidemiology - XI (Epidemiologic Research Designs: Experimental/Interventional Studies) Betty C. Jung, RN, MPH, CHES.
Information Mastery: A Practical Approach to Evidence-Based Care Course Directors: Allen Shaughnessy, PharmD, MMedEd David Slawson, MD Tufts Health Care.
Are sham operations and placebos justifiable in research? Leslie J. Kohman, MD SUNY Upstate Medical University Syracuse, NY Cardiothoracic Ethics Forum:
Lecture 16 (Oct 28, 2004)1 Lecture 16: Introduction to the randomized trial Introduction to intervention studies The research question: Efficacy vs effectiveness.
1 Experimental Study Designs Dr. Birgit Greiner Dep. of Epidemiology and Public Health.
QCOM Library Resources Rick Wallace, Nakia Woodward, Katie Wolf.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2012.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Evidence-Based Journal Article Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department.
How to Analyze Therapy in the Medical Literature (part 2)
How to Analyze Therapy in the Medical Literature: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
EBM --- Journal Reading Presenter :顏志維 Date : 2005/10/17.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2014.
Lecture 5 Objective 14. Describe the elements of design of experimental studies: clinical trials and community intervention trials. Discuss the advantages.
Information Mastery: A Practical Approach to Evidence-Based Care Course Directors: Allen Shaughnessy, PharmD, MMedEd David Slawson, MD Tufts Health Care.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
 Volunteer bias  Lead time bias  Length bias  Stage migration bias  Pseudodisease.
How to Analyze Therapy in the Medical Literature (part 1) Akbar Soltani. MD.MSc Tehran University of Medical Sciences (TUMS) Shariati Hospital
Critical Appraisal (CA) I Prepared by Dr. Hoda Abd El Azim.
Methodological quality of malaria RCTs conducted in Africa Vittoria Lutje*^, Annette Gerritsen**, Nandi Siegfried***. *Cochrane Infectious Diseases Group.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
Compliance Original Study Design Randomised Surgical care Medical care.
EBM: Randomized Controlled Trials Gil C. Grimes, MD 10 August 2006.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.
/ 161 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine EBM Therapy Articles Dr. Zekeriya Aktürk
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
Making Randomized Clinical Trials Seem Less Random Andrew P.J. Olson, MD Assistant Professor Departments of Medicine and Pediatrics University of Minnesota.
1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.
European Patients’ Academy on Therapeutic Innovation Blinding in clinical trials.
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Obtaining and Describing Samples
Francis KL Chan Department of Medicine & Therapeutics CUHK
Alcohol, Other Drugs, and Health: Current Evidence
Alcohol, Other Drugs, and Health: Current Evidence
HOPE: Heart Outcomes Prevention Evaluation study
Randomized Trials: A Brief Overview
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES study Jelena Savović1, Becky Turner2, David.
Experimental Studies.
Three Steps to Interpret Clinical Trials
Presentation transcript:

Is it True? Evaluating Research about a Therapy Allen F. Shaughnessy, PharmD, MmedEd Tufts University School of Medicine Department of Family Medicine David C. Slawson, MD The University of Virginia, Department of Family Medicine

2

Task 3: Clarification Now let’s say that the same patient has heard from a friend that there is a vitamin that will help prevent migraines. What study design could answer the question of whether there is a vitamin that is useful in preventing migraine headaches in this patient?

4 Study Methods to Answer This Question Epidemiology: Patients taking a vitamin are less likely to have migraines Pharmacology: Drug x affects cerebral vasculature in rat brain isolates Case report: “It worked on one patient” Case-series: “It worked on a bunch of patients” Randomized controlled trial: 1/2 get drug, 1/2 placebo. No one knows who ‘til the end who took what

The “Danger” of Natural History Studies For each 1% decline in hemoglobin A1c, decrease in mortality, stroke, CHD,.... Women taking HRT and CVD mortality.

The “Danger” of Natural History Studies Compliance Effect! Known as Factor X

8 Validity Internal validity: How well was the study done? Do the results reflect the truth? External validity: can I apply these results to MY patients?

9 Was it a randomized controlled trial? Randomization is the best protection against being mislead

10 32 controlled trials of anticoagulation in acute MI Results by type of study: Chalmers TC, et al. N Engl J Med 1977;297: The value of randomization

11 Was allocation assignment “concealed”? Did investigators know to which group the potential subject would be assigned before enrolling them?

12 Importance of concealed allocation Trials with unconcealed allocation consistently overestimate benefit by ~40% Schulz KF, Chalmers I, Hayes RJ, et al. JAMA 1995;273: Schulz KF, Grimes DA. Lancet 2002;359: Pildal J, et al. Int J Epidemiol 2007;36: Moher D, et al. Lancet 1998;352:

13 Was allocation assignment “concealed”? Concealed allocation  blinding Blinding can occur without concealed allocation Surfactant in the NICU Allocation can be concealed in an unblinded study PT vs surgery for knee DJD Moseley JB, O'Malley K, Petersen NJ, et al. N Engl J Med 2002; 347:81-8.

14 Potential Subjects Conducting a Study Actual Subjects A B Randomization Blinding, etc Trial starts Concealed Allocation

15 Importance of concealed assignment Meta-analysis of trials evaluating screening mammography In studies in which allocation wasn’t concealed Higher SE status, education level in screened group Age disparity (average 6 mo older in the unscreened group) Richer, smarter, younger Trials with concealed allocation = screening harmful! No effect or increased mortality 20% more mastectomies Lancet Jan 8, 2000; Oct 20, 2001

Potential Subjects Conducting a Study Actual Subjects A B Randomization Blinding, etc Trial starts Concealed Allocation Mammography Study Sign-up Number Group Patient name 1 Mamm. 2No Mamm 3Mamm 4No Mamm 5No Mamm 6Mamm 7Mamm 8No Mamm 9Mamm 10No Mamm 11Mamm 12Mamm 13No mamm 14No mamm 15Mamm Sara Smith Jill Jones Wendy Walsh Linda Lucky

17 Technical Nitpicking? Could this really make a difference? Cumulative database: ~500,000 women Current policy is based on very small differences: Deaths in unscreened women902 Deaths in screened women837 Death difference (of 456,349) 65! Systematic bias is not “random error” for which meta- analysis can compensate

18 Mundus Vult Decipi “The world wishes to be deceived” People would rather be deceived than have the truth cause anxiety Caleb Carr, Killing Time

19 “YOU WANT ANSWERS??!!! “I WANT THE TRUTH!!” “YOU CAN’T HANDLE THE TRUTH!!” Jack Nicholson and Tom Cruise “A Few Good Men”

20 Nonfebrile Seizure Incidence

21 Were all the patients properly accounted for at its conclusion? Complete follow-up? “Intention to treat” analysis? Patients are analyzed in the groups to which they are assigned Attempts to reflect “real world” clinical situations in which not all patients follow treatment recommendations Watch when they compare only compliers with compliers and non- compliers Compliant subjects always do better overall

22 Was study “double-blinded”? Did the patients know to which group they were assigned? Did the treating physician know? Did investigators assessing outcomes know (“triple- blinding” – up to 7 levels!)? Judicial assessor blind + allocation concealment = surgery RCTs Schulz KF. Ann Int Med 2002;136:254-9.

23 Were intervention and control groups similar? See Table 1 of most studies Randomization is best way to avoid bias, though imbalances still can occur (especially if allocation was not concealed) Small differences sometimes are important

24 Task 4.